PBRM1 and nonpapillary renal cell carcinoma: Hence it is possible that the finding of PBRM1 mutations in our 5 ccRCC patients correlates with response to rapalog therapy, though not seen in the pre-treatment tumor specimen, rather than representing a mechanism of resistance.